Frequency detection of the known DPYD alleles in the studied subjects using oligonucleotide microarray

Progress in Biochemistry and Biophysics

Volumn 31, Issue 11, 2004, Pages 1031-1037

  Wen, Si Yuan ^a   Wang, Xiao Yun ^a,b   Zhang, Min Li ^a   Wang, Sheng Qi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

DPYD gene; Genotyping; Olignucleotide microarray; Pharmacogenomics

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE;

ACCURACY; ARTICLE; CANCER; CONTROLLED STUDY; DNA MICROARRAY; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MUTATION; NEPHROSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 14844352236     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Takeda Y, Yoshizaki I, Nonaka Y, et al. Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo. Anticancer Drugs, 2001, 12 (8): 691-698
2. Kono T, Ishii M, Negoro N, et al. Scleroderma-like reaction induced by uracil-tegafur (UFT), a second-generation anticancer agent. J Am Acad Dermatol, 2000, 42 (3): 519-520
3. Mattison L K, Soong R, Diasio R B. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics, 2002, 3 (4): 485-492
4. Gardiner S J, Begg E J, Robinson B A. The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil. Adverse Drug React Toxicol Rev, 2002, 21 (1-2): 1-16
5. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer, 2004, 40 (7): 939-950
6. Wei X, McLeod H L, McMurrough J, et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest, 1996, 98 (3): 610-615
7. Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol, 2003, 8 (3): 132-138
8. Hsiao H H, Yang M Y, Chang J G, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol. 2004, 53 (5): 445-451
9. Gross E, Ullrich T, Seck K, et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat, 2003, 22 (6): 498-502
10. van Kuilenburg A B, de Abreu R A, van Gennip A H. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem, 2003, 40 (Pt 1): 41-45
11. Wen S Y, Wang H, Sun O J, et al. Rapid detection of the known SNPs of CYP2C9 using oligonueleotides microarray. World Journal of Gastroenterology, 2003, 9 (6): 1342-1346
12. Bertilsson L. Geographical/interracial difference in polymorphic drug oxidation. Clin Pharmacokinet, 1995, 29 (3): 192-209
13. Pastinen T, Raitio M, Lindroos K, et al. A system for specific, high-throughput genotyping by allele-specific primer extension on microarrays. Genome Res, 2000, 10 (7): 1031-1042
14. Gerry N P, Witowski N E, Day J, et al. Universal DNA microarray method for multiplex detection of low abundance point mutations. J Mol Biol, 1999, 292 (2): 251-262
15. Iwasaki H, Ezura Y, Ishida R, et al. Accuracy of genotyping for single nucleotide polymorphisms by a microarray-based single nucleotide polymorphism typing method involving hybridization of short allele-specific oligonucleotides. DNA Res, 2002, 9 (2): 59 -62